新型CD6靶向CAR-T细胞治疗T-ALL:基因编辑防自相残杀的安全高效策略
本研究利用公共单细胞转录组数据发现CD6在T-ALL中广泛表达且表达谱较CD7更局限。采用CRISPR/Cas9 RNP在CD19 CAR-T模型中敲除CD6可降低基线活化并提升抗原刺激后TNF-α(+)IFN-γ(+)细胞比例。构建的CD6敲除靶向CD6 CAR-T(6KO-6CAR)在体外对多种CD6(+) T-ALL细胞系表现出特异性激活和杀伤作用。
要点
- CD6在T-ALL广泛表达且表达谱较CD7更局限,安全性更优
- CD6敲除可降低CAR-T基线CD25表达并提升TNF-α(+)IFN-γ(+)比例
- 6KO-6CAR在体外对CD6(+) T-ALL细胞系有特异性激活和杀伤
核心结论
- CD6是T-ALL高覆盖且安全性良好的新靶点,敲除内源性CD6可整体优化CAR-T功能状态。
- 基于CRISPR/Cas9构建6KO-6CAR可解决自相残杀并增强抗肿瘤功能,具临床转化潜力。
研究设计与样本
- 利用公共scRNA-seq数据分析T-ALL患者及健康供者骨髓细胞中CD6与CD7表达谱差异。
- 在CD19 CAR-T模型中用CRISPR/Cas9 RNP敲除CD6,评估表型与活化状态。
- 构建CD6敲除的靶向CD6 CAR-T(6KO-6CAR)并评估体外功能。
主要发现
- scRNA-seq显示CD6在T-ALL广泛表达,较CD7表达谱更局限。
- CD19 CAR-T模型中CD6敲除后基线CD25表达降低(P<0.05)。
- 抗原刺激后TNF-α(+)IFN-γ(+)细胞比例更高(P<0.05)。
- 6KO-6CAR对MOLT-4、CCRF-CEM、Jurkat细胞系CD107a表达显著上调(均P<0.001)。
- 6KO-6CAR对上述细胞系杀伤作用显著(均P<0.05)。
临床怎么用
- CD6可作为T-ALL CAR-T治疗的新靶点,其表达谱较CD7更局限。
- CRISPR/Cas9敲除内源性CD6可同步防止自相残杀并优化CAR-T功能。
- 6KO-6CAR在体外对多种CD6(+) T-ALL细胞系有特异性激活和杀伤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore a novel strategy that addresses the dual challenges of fratricide and on-target off-tumor toxicity in current chimeric antigen receptor T-cell (CAR-T) therapy for T-cell acute lymphoblastic leukemia (T-ALL) and to develop a safe and efficacious anti-T-ALL CAR-T product by identifying a new target and compatible gene-editing approach. Methods: Public single-cell RNA sequencing (scRNA-seq) datasets were utilized to analyze bone marrow cells extracted from patients with T-ALL and healthy donors, evaluating the differential expression profiles of CD6 and CD7. In investigating the endogenous role of CD6 in CAR-T cells, the CRISPR/Cas9 RNP system was first employed in a CD19 CAR-T model to evaluate the impact of CD6 knockout on the phenotype and activation status of CAR-T cells. Subsequently, CD6-knockout, CD6-targeted CAR-T cells (6KO-6CAR) were constructed, and their functional activities were evaluated. Results: scRNA-seq analysis revealed that CD6 is broadly expressed in T-ALL. Compared with the traditional target CD7, which is also expressed in a subset of normal hematopoietic stem/progenitor cells and myeloid cells, CD6 exhibits a more restricted expression profile, exhibiting superior safety characteristics. Studies on the CD19 CAR-T model indicated that CD6 knockout enables CAR-T cells to maintain a superior functional state: their baseline activation level (CD25 expression) was reduced (P<0.05) while generating a higher proportion of TNF-α(+)IFN-γ(+) cells (P<0.05) upon antigen stimulation. The further constructed 6KO-6CAR cells exhibited potent specific activation (significantly upregulated CD107a expression level, all P<0.001) and cytotoxicity (all P<0.05) against multiple CD6(+) T-ALL cell lines (MOLT-4, CCRF-CEM, and Jurkat) in vitro. Conclusion: CD6 is a novel therapeutic target for T-ALL with high coverage and a favorable safety profile, and knocking out endogenous CD6 globally optimizes the intrinsic functional state of CAR-T cells. Constructing 6KO-6CAR based on the CRISPR/Cas9 technology addresses fratricide in CAR-T cells while enhancing their antitumor functionality, thereby providing a novel immunotherapy regimen with safety and clinical translational potential for relapsed/refractory T-ALL. 目的: 探索克服急性T淋巴细胞白血病(T-ALL)嵌合抗原受体T细胞(CAR-T细胞)疗法中自相残杀与非肿瘤靶向毒性双重障碍的新策略,通过鉴定新靶点及其相应基因编辑方案,开发一种安全、高效的抗T-ALL CAR-T产品。 方法: ①利用公共数据库单细胞转录组测序(scRNA-seq)数据分析T-ALL患者及健康供者骨髓细胞,评估CD6与CD7的表达谱差异。②为探究CD6在CAR-T细胞中的内源性作用,首先采用CRISPR/Cas9 RNP系统在CD19 CAR-T模型中,评估CD6敲除对CAR-T细胞表型和活化状态的影响;随后,构建CD6敲除的靶向CD6 CAR-T细胞(6KO-6CAR)并评估其功能。 结果: scRNA-seq数据显示,CD6在T-ALL中广泛表达,且相较于在部分正常造血干/祖细胞及髓系细胞中均表达的传统靶点CD7,CD6的表达谱更为局限,展现出更优的安全性特征。CD19 CAR-T模型中的研究表明,CD6敲除能使CAR-T细胞维持更优的功能状态:其基线活化水平(CD25表达)降低(P<0.05),同时在抗原刺激下能产生更高比例的TNF-α(+)IFN-γ(+)细胞(P<0.05)。进一步构建的6KO-6CAR细胞在体外对多种CD6(+) T-ALL细胞系(MOLT-4、CCRF-CEM、Jurkat)表现出较强的特异性激活(CD107a表达显著上调,均P<0.001)及杀伤作用(均P<0.05)。 结论: CD6是一个具有高覆盖性和良好安全性的T-ALL治疗新靶点,同时敲除内源性CD6后还能从整体上优化CAR-T细胞的内在功能状态。基于CRISPR/Cas9技术构建6KO-6CAR的策略,能在解决CAR-T细胞自相残杀的同时增强其抗肿瘤功能,这为T-ALL提供了一种兼具安全性与应用前景的新型免疫治疗方案。.
引用
- Shangguan YT, Xie LL, Liu WB, et al. [Novel CD6-targeted CAR-T cell therapy for T-cell acute lymphoblastic leukemia: a safe and efficient strategy to prevent fratricide through gene editing]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42409731. doi:10.3760/cma.j.cn121090-20260130-00068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。